Apretude

News article announcing the U.S. Food and Drug Administration’s approval of Apretude

A clinical practice guideline

In a trial involving sub-Saharan African women, intramuscular cabotegravir was superior to oral TDF/FTC for preventing HIV-1 infection.

Long-acting injectable holds advantages over daily pills for pre-exposure prophylaxis against HIV, says ViiV executive.

Although both products for HIV prevention were generally safe, well tolerated, and effective, cabotegravir was superior to TDF-FTC in preventing HIV infection in women.

Commentary on a study evaluating the safety and efficacy of bictegravir and cabotegravir in pregnancy.

Pre-exposure prophylaxis (PrEP), a potent medication for HIV prevention, shows promise for reducing HIV disparities. However, PrEP is not equitably utilized by all races and ethnicities in the USA. Its uptake is especially low among African Americans, who are disproportionately impacted by HIV. Understanding factors influencing low PrEP uptake among diverse priority groups of African

This phase 1 study assessed safety, tolerability, pharmacokinetics, and acceptability of cabotegravir in 47 HIV-negative adult Chinese men at low risk of acquiring HIV-1.

This Industry Update provides an overview of the some of the key events in the pharmaceutical world in December 2021.

Osra Medical, an LGBTQ+ primary care Practice, a GGBA member and an NGLCC Certified LGBTBE Business Enterprise, announced they are now the first to provide injectable PrEP, Apretude, in San Francisco.